Analysis of Revenues
Paying user area
Try for free
Gilead Sciences Inc. pages available for free this week:
- Cash Flow Statement
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Analysis of Geographic Areas
- Price to FCFE (P/FCFE)
- Present Value of Free Cash Flow to Equity (FCFE)
- Operating Profit Margin since 2005
- Debt to Equity since 2005
- Total Asset Turnover since 2005
- Price to Sales (P/S) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Gilead Sciences Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Revenues as Reported
Gilead Sciences Inc., income statement, revenues
US$ in millions
| 12 months ended: | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| HIV | |||||||||||
| Liver Disease | |||||||||||
| Veklury | |||||||||||
| Cell Therapy | |||||||||||
| Trodelvy | |||||||||||
| Oncology | |||||||||||
| Other | |||||||||||
| Product sales |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
The annual revenue data reveals several notable trends across various product segments.
- HIV
- The revenue from HIV shows a general upward trend over the five-year period, increasing from $16,938 million in 2020 to $19,612 million in 2024. Despite a slight dip in 2021, the figures recover and continue to grow steadily.
- Liver Disease
- Revenue generated from Liver Disease remains relatively stable with a minor decline from $2,924 million in 2020 to $2,784 million in 2023, followed by a rebound to $3,021 million in 2024. This indicates consistent demand with some fluctuations.
- Veklury
- This product shows a marked rise in revenue from $2,811 million in 2020 to a peak of $5,565 million in 2021, followed by a declining trend to $1,799 million in 2024. This pattern suggests a possible one-time increase or market saturation after an initial surge.
- Cell Therapy
- Cell Therapy exhibits substantial growth, progressing from $607 million in 2020 to $1,974 million in 2024. This steady increase reflects expanding market penetration or product development success in this segment.
- Trodelvy
- Revenue for Trodelvy starts relatively low at $49 million in 2020 but experiences rapid growth each year, reaching $1,315 million by 2024, indicating strong market adoption and increasing sales momentum.
- Oncology
- Oncology revenues demonstrate significant and consistent growth, nearly quintupling from $656 million in 2020 to $3,289 million in 2024. This is indicative of a strategically important and expanding area of the business.
- Other
- The Other category experiences a slight decline from $1,026 million in 2020 to $889 million in 2024, suggesting shrinking revenue from miscellaneous sources or product lines.
- Product sales (total)
- Total product sales show an overall positive trend, increasing from $24,355 million in 2020 to $28,610 million in 2024. Although there was a slight decrease in 2022 and 2023 relative to 2021, the total revenue rebounds in 2024, reflecting overall sales growth.
In summary, while established segments such as HIV and Liver Disease maintain stable or growing revenue, newer or focused areas like Cell Therapy, Trodelvy, and Oncology show robust expansion. Conversely, Veklury exhibits a peak and subsequent decline, suggesting shifting demand dynamics. The total product sales indicate overall growth, supported by strong performances in emerging segments.